PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen November 14, 2024
U.S.-Based Shearwater Health Expands to Chennai, Opening New Opportunities for India’s Clinical Talent November 11, 2024
